Orvepitant

Orvepitant

SCHEMBL2484384

Cc1cc(F)ccc1[C@H]1C[C@@H](N2CCN3C(=O)CC[C@H]3C2)CCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1.Cl

nearest known ligand 0.99

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TACR1

The experimentally established mechanism targets of Orvepitant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TACR1 known ✓ P25103 19/20 0.99
SIGMAR1 Q99720 2/20 0.99
PTAFR P25105 1/20 0.99
CYP3A4 P08684 2/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Orvepitant SCHEMBL5360752 1.00 TACR1 (0.99) TACR1SIGMAR1PTAFRCYP3A4
Orvepitant SCHEMBL30110395 1.00 TACR1 (0.99) TACR1SIGMAR1PTAFRCYP3A4
Orvepitant SCHEMBL1421784 0.99 TACR1 (1.00) TACR1SIGMAR1PTAFRCYP3A4
Orvepitant SCHEMBL21931158 0.99 TACR1 (1.00) TACR1SIGMAR1PTAFRCYP3A4
Orvepitant SCHEMBL19581227 0.99 TACR1 (1.00) TACR1SIGMAR1PTAFRCYP3A4
Orvepitant SCHEMBL23895405 0.99 TACR1 (1.00) TACR1SIGMAR1PTAFRCYP3A4
Orvepitant SCHEMBL19117640 0.99 TACR1 (1.00) TACR1SIGMAR1PTAFRCYP3A4
Orvepitant SCHEMBL2179896 0.99 TACR1 (1.00) TACR1SIGMAR1PTAFRCYP3A4
Orvepitant SCHEMBL2484579 0.99 TACR1 (1.00) TACR1SIGMAR1PTAFRCYP3A4
Orvepitant SCHEMBL29373789 0.99 TACR1 (1.00) TACR1SIGMAR1PTAFRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2117535-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS GLAXO GROUP LTD (GB) 2011-10-26 EP disclosed
EP-2117562-B1 PHARMACEUTICAL COMPOSITIONS COMPRISING NK1 RECEPTOR ANTAGONISTS AND SODIUM CHANNEL BLOCKERS GLAXO GROUP LTD (GB) 2011-10-26 EP disclosed